China Biotech Services Holdings Ltd. said it completed the issuance of convertible bonds under a specific mandate, issuing convertible bonds with an aggregate principal amount of US$35 million to the subscriber on Feb. 20, 2026. The company also announced an adjustment to its outstanding 2024 convertible bonds: US$6.0 million principal remains outstanding, with the conversion price adjusted to HK$1.11 per share (from HK$1.20) and the maximum shares issuable on full conversion increased to 42,432,432, effective Feb. 20, 2026. https://www.hkexnews.hk
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Biotech Services Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260223-12027201), on February 23, 2026, and is solely responsible for the information contained therein.